Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 7/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15080706 | 1.00 | ADORA1 (0.36) | ADORA1ADORA2AADORA3ADORA2BRXFP1 | |
| SCHEMBL15080702 | 0.93 | RXFP1 (0.35) | ADORA1ADORA2AADORA3ADORA2BRXFP1 | |
| SCHEMBL12226013 | 0.93 | RXFP1 (0.35) | ADORA1ADORA2AADORA3ADORA2BRXFP1 | |
| SCHEMBL15080701 | 0.87 | ADORA1 (0.44) | ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL12226018 | 0.87 | ADORA1 (0.44) | ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL15426673 | 0.86 | ADORA2A (0.51) | ADORA1ADORA2AADORA3ADORA2BRXFP1 | |
| SCHEMBL12226009 | 0.80 | ADORA1 (0.45) | ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL15080703 | 0.80 | ADORA1 (0.45) | ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL15080705 | 0.79 | RXFP1 (0.35) | ADORA1ADORA2AADORA2BRXFP1P2RX1 | |
| SCHEMBL12226016 | 0.79 | RXFP1 (0.35) | ADORA1ADORA2AADORA2BRXFP1P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245195-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245195-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | PDE3A, PDE2A, PDE6C | ADORA1 18/4885ADORA2A 25/4885ADORA3 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.